Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a23c8ab8d8a00abb

Jump to content

SCTV01C

From Wikipedia, the free encyclopedia

SCTV01C
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Identifiers
CAS Number

SCTV01C is a COVID-19 vaccine candidate developed by Sinocelltech.[2][3][4]

References

[edit]
  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Adenovirus Vectored or mRNA COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043311. Retrieved 14 September 2021.
  3. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043285. Retrieved 14 September 2021.
  4. ↑ "Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Unvaccinated". United States National Library of Medicine. 8 December 2021. NCT05148091. Retrieved 8 December 2021.


Retrieved from "https://en.wikipedia.org/w/index.php?title=SCTV01C&oldid=1247453077"